96-well liquid survival assay for geroprotector compound discovery in C. elegans
Caenorhabditis elegans is the workhorse organism of aging research: a 3-day generation time, ~2-3 week adult lifespan, fully sequenced genome, and transparent body make it the fastest whole-animal system for testing whether a small molecule can extend healthy lifespan before committing to slower, costlier mammalian studies.
C. elegans shares roughly 60–80% of its genes with humans, including deeply conserved aging-regulatory pathways: insulin/IGF-1 signaling (IIS), target-of-rapamycin (TOR), AMP-activated kinase (AMPK), and sirtuins. Its short lifespan (weeks, not years) allows a full survival curve to be collected in the time a mouse study would still be dosing animals.
A synchronized cohort is obtained by bleaching gravid adults to release eggs, then hatching them in the absence of food (L1 arrest) to align developmental stage before switching to a food source. This produces a population that reaches the L4 larval stage — and thus adulthood — within hours of each other, which is essential for clean survival statistics.
Liquid culture (as opposed to solid NGM agar plates) allows automated liquid handling: compounds, food, and worms are all pipetted robotically into 96-well plates, enabling thousands of compounds to be tested per week with modest labor.
FUdR (5-fluoro-2'-deoxyuridine) is added at 25–100 µM to block embryo development inside the hermaphrodite, preventing self-fertilized progeny from confounding the adult worm count during the weeks-long assay.
A typical primary screening plate reserves two columns for controls: vehicle-only (DMSO, matched concentration) and a positive control geroprotector (often 100 µM metformin or 10 µM rapamycin). Remaining columns carry the test library, often at a single screening dose (e.g., 25 µM) for primary screens, or a full 6-8 point dose-response for confirmed hits.
Each well receives live or UV-killed E. coli OP50 as food — UV-killed bacteria are increasingly preferred because they prevent confounding effects of bacterial proliferation altering compound concentration or causing late-life infection, a common cause of death artifactually scored as "natural" aging.
Plates are sealed with gas-permeable membranes and incubated at 20°C, the standard temperature for C. elegans lifespan work, since temperature strongly affects rate of aging (a 4°C increase can nearly halve lifespan).
Modern lifespan screening facilities use liquid-handling robots (e.g., acoustic dispensers, multichannel pipetting heads) to distribute worms, food, and compound stock solutions across plates with coefficient of variation under 10% for worm number per well.
Plates are imaged on flatbed scanners or automated microscopes at defined intervals. Because C. elegans in liquid is optically simple (a transparent ~1 mm tube-shaped animal), image-based motion analysis can score thousands of worms per plate without manual handling, which is the key innovation that made genome- and compound-library-scale lifespan screening feasible.
Before aging-related decline can be measured, every well must be characterized while animals are young and healthy. This baseline is the reference against which all later decline — and any compound-driven preservation of function — is measured.
In liquid, C. elegans performs a rapid sinusoidal "thrashing" locomotion distinct from the crawling gait used on solid agar. Thrash frequency (body bends per second) is a sensitive, quantitative proxy for neuromuscular health and is one of the earliest-declining metrics with age, often dropping measurably before survival itself changes.
Baseline video capture (typically 10-30 second clips per well) establishes each well's starting thrash frequency and path coverage. Automated tracking software segments each worm silhouette from background, fits a midline, and computes bend frequency and amplitude frame-by-frame.
Several variables are checked before treatment effects are trusted:
• Starting population size per well — undercounts inflate apparent lifespan (fewer censored animals) • Bacterial density — excess food can itself modulate lifespan via dietary restriction-like signaling • Temperature uniformity across the incubator — edge wells often run cooler • Compound solvent (DMSO) toxicity — must stay below 0.5–1% v/v to avoid its own lifespan-shortening effect
Wells failing quality control (bacterial contamination, abnormal starting motility, visible plate evaporation) are flagged and excluded before the assay proceeds to longitudinal scoring.
DMSO above ~1% v/v is itself measurably toxic to C. elegans, shortening lifespan independent of any active compound — a classic confound that invalidates naive hit calls if vehicle concentration is not carefully matched across all wells.
From roughly day 8 onward, natural attrition begins. Worms are scored on a fixed schedule for movement in response to stimulus, and those that fail to respond are recorded as dead — the fundamental unit of every survival curve.
A worm is scored dead when it fails to respond to a mechanical stimulus (plate tap or gentle prod with a platinum pick) and shows no spontaneous movement, and no pharyngeal pumping, over an observation window. In liquid/automated formats, death is scored as complete cessation of body movement across sequential imaging frames, often confirmed over 2 consecutive scoring days to avoid false positives from quiescent (but alive) animals.
Automated systems (e.g., WorMotel-style microchamber arrays, or whole-well optical flow analysis) compute a movement index per worm per timepoint; a sustained drop to near-zero triggers a death call that is spot-checked against manual scoring.
Not every disappearance is a true aging-related death. Worms that crawl up the well wall and desiccate, are lost to internal hatching ("bagging", rare when FUdR is used), or wells contaminated by fungal growth must be censored — removed from the risk set at the timepoint they were last known alive, rather than scored as dead.
Kaplan-Meier estimation explicitly accounts for censored data: censored individuals contribute information up to their last observed timepoint without being counted as an event, keeping the survival estimate unbiased as long as censoring is non-informative (unrelated to treatment).
Raw death events collected over three weeks are assembled into survival curves per well and per compound. Statistical comparison against vehicle control identifies which compounds produced a genuine, reproducible lifespan extension rather than noise.
For each well or pooled condition, the fraction of animals still alive is plotted against time, producing a step-function Kaplan-Meier curve. Key summary statistics extracted include median lifespan (time at which 50% of the cohort has died), maximum lifespan (typically the 90th percentile survivor age), and the full curve shape, which can reveal whether a compound delays the onset of death, slows the rate of decline, or both.
The log-rank test compares the full survival distribution between treated and control groups, weighting all timepoints, and is more statistically powerful than comparing medians alone because it uses the entire curve shape rather than a single point estimate.
A compound that shifts median lifespan by only 8% but significantly compresses the "mortality deceleration" at late ages may be more biologically interesting than one that shifts the median more but leaves maximum lifespan unchanged — curve shape matters, not just the median.
Because thousands of compounds are tested, multiple-hypothesis correction (false discovery rate control) is essential — with a naive p<0.05 threshold across a 2,000-compound library, ~100 false positives would be expected by chance alone.
Common artifact sources include: compounds that reduce bacterial food density (mimicking dietary restriction non-specifically), compounds with antimicrobial activity that alter the OP50 lawn, and compounds that simply immobilize worms without killing them (scored as false "deaths" or, conversely, mistaken for survival if paralyzed-but-alive animals are miscounted).
Confirmed hits are re-tested in fresh cohorts, ideally by a blinded scorer, and profiled across a dose range to confirm a plausible pharmacological dose-response relationship before further mechanistic study.
A confirmed hit is placed in context by comparing its magnitude of effect and genetic requirements against the two best-characterized pharmacological longevity interventions in C. elegans: rapamycin and metformin — and by testing whether the hit requires the same conserved signaling pathways.
Two deeply conserved nutrient-sensing pathways dominate C. elegans lifespan biology. Reduced insulin/IGF-1 signaling (IIS) through the daf-2 receptor releases the transcription factor DAF-16/FOXO to enter the nucleus and activate stress-resistance and longevity genes, extending lifespan up to 2-fold in daf-2 mutants. Separately, inhibiting TOR (target of rapamycin) — either genetically (rsks-1, let-363 knockdown) or pharmacologically with rapamycin — extends lifespan by slowing protein synthesis and boosting autophagy, partially overlapping with but genetically separable from the IIS pathway.
Metformin acts differently: it activates AMPK (via mild inhibition of mitochondrial complex I) and also affects bacterial folate/methionine metabolism in the OP50 food source, since C. elegans lifespan extension by metformin is partly indirect, mediated through the microbe it eats.
To determine mechanism, the confirmed hit compound is retested in mutant backgrounds: daf-16(null) worms should lose the lifespan benefit of an IIS-acting hit; rsks-1 or raga-1 mutants (TOR pathway) should blunt a TOR-acting hit's effect if epistatic. If lifespan extension persists in these mutants, the compound likely acts through an independent or novel pathway — often the most valuable outcome, since it suggests a new druggable target.
Transcriptomic profiling (RNA-seq) of treated versus control worms, alongside reporter strains (e.g., a daf-16::GFP nuclear translocation reporter, or a TOR-pathway autophagy reporter), provide orthogonal mechanistic evidence beyond survival curves alone.
The gold-standard translational path is: C. elegans hit → confirm in Drosophila → confirm in mouse lifespan cohorts (the NIA Interventions Testing Program). Rapamycin and metformin both cleared this bar, which is why they anchor comparisons for every new nematode hit.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Rapamycin | TOR complex 1 (TORC1) | Inhibits mTOR/TOR signaling, boosts autophagy, reduces translation | ~10–20% lifespan extension; conserved to mice (NIA ITP) |
| Metformin | Mitochondrial complex I / AMPK | Mild ETC inhibition activates AMPK; alters bacterial folate metabolism | Widely used human diabetes drug; repurposing candidate |
| Resveratrol | Sirtuins (SIR-2.1) | Proposed sirtuin activation; effects strain/diet-dependent | Historic geroprotector; mixed reproducibility |
| New hit compound | TBD | Determined by epistasis and transcriptomic profiling | Candidate for translational follow-up if pathway-independent |